Eli Lilly-Backed Scribe Therapeutics Seeks $107.2 Million in IPO
2026-07-20 12:24:50
Scribe Therapeutics Inc. is seeking to raise as much as $107.2 million in a US initial public offering, according to Bloomberg. The clinical-stage gene therapy developer focuses on treatments for heart diseases.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
